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Background: Left ventricular ejection fraction (LVEF) is in continuum with respect to heart failure status and associated risk. Therefore, there is a 
rationale for cardiac resynchronization therapy (CRT) in patients with preserved LVEF. 
Methods: In the MADIT-CRT trial, the echocardiography core laboratory assessed the baseline LVEF independent of the enrolling centers and 
identified a range of LVEF’s including those >30%. Echocardiographic response with CRT, defined as percent change in left ventricular end-diastolic 
volume (LVEDV), was analyzed in three LVEF groups: <21%, 21-30% and >30%. The primary endpoint was heart failure (HF) or death. 
Results: LVEF was evaluated in 1074 patients with CRT-D (crossovers excluded).There were 410 (38%) patients with LVEF>30% (in the range of 
31-45%), mean LVEF was 32.3±2.1%. The reduction in LVEDV was significantly larger in patients with LVEF>30% compared to patients with LVEF of 
21-30% and <21% (-22.2±12.3% vs. -19.8±10.7, vs. -11.2±5.9; p=0.004)(Figure). After adjustment for clinical covariates, CRT:ICD treatment did 
not reduce the risk of HF/Death in those with LVEF<21% (HR=1.25, 95% CI: 0.46-3.36, p=0.66), but did reduce the risk in those with LVEF 21-30% 
(HR=0.63, CI:0.49-0.81, p<0.001) and in those with LVEF >30% (HR=0.62, CI:0.44-0.89, p=0.009). 
Conclusions: The clinical benefit of CRT is present in patients with LVEF>30%, while the echocardiographic response is even more pronounced. 
Patients with LVEF <21% did not show clinical benefit from CRT-D.
 
